Alpha 2.0
Login Register
» Authors » S Siena

S Siena

Explore the profile of S Siena including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 158
Citations 2483
Followers 0
Related Specialties
Oncology
Hematology
General Surgery
Top 10 Co-Authors
M Bregni
A M Gianni
G Bonadonna
M Di Nicola
A Sartore-Bianchi
F Ravagnani
C Tarella
P Pedrazzoli
M Magni
R Schiavo
Published In
Ann Oncol
Haematologica
Blood
Bone Marrow Transplant
ESMO Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
Tosi F, Salvatore L, Tamburini E, Artale S, Lonardi S, Marchetti S, et al.
ESMO Open . 2024 Oct; 9(10):103929. PMID: 39357124
Background: Sustained clinical complete remissions were reported in all of 23 mismatch repair deficient/microsatellite instable (dMMR/MSI) locally advanced rectal cancer (LARC) patients treated with dostarlimab alone in a recent phase...
2.
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
Pizzutilo E, Agostara A, Oresti S, Signorelli D, Stabile S, Lauricella C, et al.
ESMO Open . 2024 Jun; 9(6):103592. PMID: 38878323
Background: Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth factor receptor (EGFR) mutations, constituting 80%-90% of all EGFR alterations....
3.
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
Powell C, Modi S, Iwata H, Takahashi S, Smit E, Siena S, et al.
ESMO Open . 2022 Aug; 7(4):100554. PMID: 35963179
Introduction: This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd. Methods: Patients who received...
4.
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment
Conte P, Ascierto P, Patelli G, Danesi R, Vanzulli A, Sandomenico F, et al.
ESMO Open . 2022 Feb; 7(2):100404. PMID: 35219244
Background: Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease resulting from exposure to drugs causing inflammation and possibly interstitial fibrosis. Antineoplastic drugs are the primary cause...
5.
Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management
Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, et al.
ESMO Open . 2021 Dec; 7(1):100338. PMID: 34920290
Background: Vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs) are widely used in cancer treatment and burdened by cardiovascular toxicity. The majority of data come from clinical trials,...
6.
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patane D, et al.
ESMO Open . 2021 May; 6(3):100156. PMID: 34044286
The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and...
7.
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
Paz-Ares L, Barlesi F, Siena S, Ahn M, Drilon A, Conley A, et al.
ESMO Open . 2021 Apr; 6(3):100113. PMID: 33930659
Background: Patient-reported outcomes (PROs) are increasingly relevant endpoints in clinical trials, contributing to our understanding of risk-benefit profiles, in addition to efficacy and safety data. We investigated the impact of...
8.
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Mauri G, Arena S, Siena S, Bardelli A, Sartore-Bianchi A
Ann Oncol . 2020 Jun; 31(9):1135-1147. PMID: 32512040
Background: Colorectal cancer (CRC) represents a major cause of cancer deaths worldwide. Although significant progress has been made by molecular and immune therapeutic approaches, prognosis of advanced stage disease is...
9.
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo E, Tosi F, Siena S
Ann Oncol . 2019 Nov; 30(Suppl_8):viii5-viii15. PMID: 31738427
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since...
10.
Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy
Russo A, Andreano A, Sartore-Bianchi A, Mauri G, Decarli A, Siena S
Cancer Epidemiol . 2019 Apr; 60:134-140. PMID: 31005829
Background: Colorectal cancer (CRC) overall incidence has been decreasing in the last decade. However, there is evidence of an increasing frequency of early-onset CRC in young individuals in several countries....